What Nexstim does

Nexstim Plc is a Helsinki-based, Nasdaq Helsinki-listed medical technology company founded in 2000 that develops navigated Transcranial Magnetic Stimulation (nTMS) systems under its SmartFocus E-field navigated TMS platform. The company's flagship NBS System 6 is an FDA-cleared and CE-marked device that uses real-time 3D imaging and electric-field modeling to precisely target brain regions and quantify stimulation dose. The system serves four primary clinical applications: pre-procedural brain mapping for neurosurgery and radiotherapy planning, therapeutic repetitive TMS for major depressive disorder (including adolescents 15-21), OCD, and chronic neuropathic pain, post-operative motor rehabilitation, and an optional TMS-EEG research module for neuroscience investigations.

Nexstim generates revenue through capital equipment sales of the NBS 6 platform to healthcare institutions and research centers, distributed via direct hospital sales and a growing distributor network — most recently evidenced by a June 2026 order for ten systems from a distributor and Australian commercial authorization. Customer segments are organized vertically around clinical use cases: neurosurgery, psychiatry and pain management, radiotherapy, neurorehabilitation, epilepsy, pediatrics, and neuroscience research. Named customers include Mayo Clinic, Charité Universitätsmedizin Berlin, Helsinki University Hospital, and UCSF, alongside US healthcare institutions participating in clinical trials. The company invests heavily in clinical evidence generation, with 170+ peer-reviewed publications covering 7,000+ patients, including meta-analyses demonstrating reductions in postoperative motor deficits and increased gross total resection rates.

The NBS 6 platform integrates with established neurosurgical and radiotherapy planning ecosystems — GammaPlan (Elekta), StealthStation (Medtronic), CyberKnife Multiplan, Brainlab iPlan — as well as with EEG systems and fMRI overlays, embedding Nexstim's functional mapping outputs into standard clinical workflows. The company also pursues co-development partnerships, including with Sinaptica Therapeutics on the SinaptiStim-R system for Alzheimer's disease, and research collaborations with the Tiny Blue Dot Foundation and academic centers on TMS-EEG biomarker validation. Recent strategic milestones include EU MDR certification of the NBS 6 diagnostics system (October 2025), Australian commercial distribution authorization (June 2026), and a EUR 1.5 million innovation loan from Finnvera (June 2024) to fund continued platform development.

Name

Nexstim

Legal name

Nexstim Plc

Website

https://nexstim.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Nexstim is a Finnish medical device company that sells the FDA-cleared and CE-marked NBS System 6, using navigated Transcranial Magnetic Stimulation with real-time E-field modeling to enable pre-surgical brain mapping, MDD/OCD/pain therapy, and post-operative motor rehabilitation for hospitals and research centers.

Ownership category

akta.pro rank

Product category

Navigated Transcranial Magnetic Stimulation Systems

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Condition-specific Digital Therapeutics (DTx) (HLACANAA)

Keywords

• Navigated TMS systems
• Pre-surgical brain mapping
• Transcranial magnetic stimulation
• Neuromodulation medical devices
• Repetitive TMS therapy

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales: Sale of NBS 6 navigated brain stimulation systems to healthcare institutions for diagnostic and therapeutic applications including pre-surgical mapping, depression therapy, and neurorehabilitation.
2. Clinical Trial Systems: Supply of neurological therapy systems for clinical trial phases targeting treatment of depression through brain stimulation and stroke rehabilitation.
3. Research Systems: Sale of research-use TMS-EEG systems for neuroscience research applications, noted as not FDA-cleared nor CE-marked.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Nexstim develops and manufactures the NBS System 6, a navigated transcranial magnetic stimulation (nTMS) platform powered by its proprietary SmartFocus E-field navigation technology. The system is used by hospitals and clinics for pre-surgical brain mapping and for delivering repetitive TMS (rTMS) therapy in major depressive disorder (MDD), obsessive-compulsive disorder (OCD), chronic neuropathic pain, and post-operative motor rehabilitation.

Product overview

Nexstim offers a unified medical device platform (NBS System 6) with SmartFocus nTMS technology as the core technology. The NBS 6 system is a single integrated platform that serves multiple clinical applications: diagnostic pre-procedural brain mapping, therapeutic treatments for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and chronic neuropathic pain, as well as post-operative motor rehabilitation. The platform integrates E-field navigated TMS with 3D imaging and supports optional TMS-EEG research module. Products include NBS System 6 as the core hardware/software platform, SmartFocus nTMS as the proprietary technology brand, various therapeutic and diagnostic applications as software/configurations, and Nexstim Podium for education/research support.

Differentiator

Problem solved

Functional benefit

Brands

• SmartFocus nTMS: Electric field navigated rTMS therapy system for treatment of major depressive disorder and other neurological conditions
• NBS 6
• Nexstim Connect
• nTMS-EEG

Products and services

• NBS System 6 (with SmartFocus nTMS technology) The NBS System 6 is Nexstim's flagship navigated TMS hardware platform, combining transcranial magnetic stimulation with E-field-based neuronavigation. It is sold to hospitals, neurosurgery departments, and therapy clinics for pre-surgical brain mapping and therapeutic rTMS applications.
• TMS-EEG Module The TMS-EEG Module is an add-on for the NBS System 6 that enables simultaneous navigated TMS and electroencephalography (EEG) recording. It is targeted at academic and clinical neuroscience research institutions investigating brain function and connectivity.
• Pre-surgical Brain Mapping (SmartFocus nTMS diagnostics) Diagnostic application of the NBS System 6 used by neurosurgery teams to non-invasively map motor and language cortical areas before tumor or epilepsy surgery, helping to plan resection corridors and reduce surgical risk.
• SmartFocus rTMS Therapy for Major Depressive Disorder (MDD) Therapeutic application of the NBS System 6 delivering navigated repetitive TMS to treat major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication.
• SmartFocus rTMS Therapy for Obsessive-Compulsive Disorder (OCD) Therapeutic application of the NBS System 6 delivering navigated repetitive TMS as a treatment for adults with obsessive-compulsive disorder.
• SmartFocus rTMS Therapy for Chronic Neuropathic Pain Therapeutic application of the NBS System 6 that uses navigated repetitive TMS to alleviate chronic neuropathic pain in adult patients, offered at specialist pain clinics.
• Post-operative Motor Rehabilitation (SmartFocus rTMS) Therapeutic application of the NBS System 6 that delivers navigated repetitive TMS to support post-operative motor rehabilitation in patients recovering from neurosurgical procedures.

Quantifiable outcome

• Meta-analysis shows nTMS motor mapping significantly reduces risk of postoperative new permanent motor deficits (OR=0.54, p=0.001) and increases gross total resection rate (OR=2.32, p<0.001)
• +2 more outcomes

Named customers5 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability5 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core and supporting.

• Sinaptica TherapeuticscoreStrategic or Co-development PartnerCo-development partnership for SinaptiStim-R precision neuromodulation system to treat Alzheimer's disease. Part of Nexstim's TMS-EEG development projects.
• Tiny Blue Dot FoundationsupportingStrategic or Co-development PartnerResearch collaboration for validation of TMS-EEG responses with functional MRI and EEG in patients with disorders of consciousness.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Large medtech incumbent with deep brain stimulation (DBS) and other neuromodulation franchises, plus neurosurgical navigation (StealthStation) that integrates with Nexstim. Represents both a workflow partner and a broader neuromodulation competitor with much greater scale.
• Boston Scientific: Operates significant neuromodulation franchises in DBS, spinal cord stimulation, and VNS. Comparable to Nexstim only in the broadest neuromodulation category but competes for hospital neurology/neurosurgery budgets and channel relationships.
• Abbott: Major neuromodulation incumbent via its DBS and spinal cord stimulation portfolios. Competes with Nexstim in the broader invasive neuromodulation market and benefits from large-scale hospital sales coverage that Nexstim lacks.

Emerging players

• Soterix Medical: Specializes in non-invasive neuromodulation including transcranial direct current stimulation (tDCS), TMS, and High-Definition tDCS. Overlaps with Nexstim in TMS-EEG research applications and adjacent neurostimulation modalities used in neuroscience research labs.
• Axilum Robotics: Developer of robotized TMS systems for clinical trials and research. Targets the same navigated/precision TMS research segment where Nexstim's TMS-EEG and SmartFocus platforms compete, particularly in automated stimulation delivery.

Direct peers

• eNeura: Developer of single-pulse TMS devices (sTMS) for acute and preventive treatment of migraine. Therapeutic TMS peer focused on a different neurological indication but competing in the broader non-invasive TMS clinical market alongside Nexstim.
• Brainsway: Israel-based developer of Deep TMS systems with FDA-cleared indications in MDD, OCD, and smoking cessation. Direct competitor in the navigated TMS therapy market, particularly for psychiatric applications where Nexstim's SmartFocus rTMS is positioned.
• MagVenture: Danish manufacturer of TMS stimulators and coils widely used in clinical psychiatry and research. Sells into the same MDD, OCD, and neuroscience research customer base as Nexstim, with comparable MagPro system offerings.
• Magstim: Pioneer and one of the largest manufacturers of TMS systems globally. Direct competitor in navigated and non-navigated TMS for research, depression, and neuroscience applications, overlapping with Nexstim's NBS platform across most clinical and research use cases.
• Neurosoft: Manufacturer of TMS and neurophysiology equipment with presence across clinical neurophysiology and research markets. Competes with Nexstim in TMS hardware sales and serves overlapping neurology and psychiatry customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nexstimoyj
• Facebookfacebook.com/nexstim
• LinkedInlinkedin.com/company/nexstim

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexstim